Genmab Q3 2026: revenue up 22% on Epkinly and pipeline; 2026 guidance maintained
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Total Revenue: Up 22% year-over-year in the first nine months of 2026, with growth across the portfolio. Adjusted Operating Profit: Grew 9% year-over-year. Darzalex Revenue: Increased 19% year-over-year; contributed approximately half of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong growth at a mid-cap biotech with 2026 revenue guidance maintained, relevant for its sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue rose 22% year-over-year in the first nine months of 2026, and adjusted operating profit grew 9%.
- 02Epkinly net product sales reached $491 million, up 47%, and Darzalex revenue rose 19%.
- 032026 revenue guidance was maintained at approximately $4.325 billion to $4.525 billion.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets